# A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia

> **NCT04074551** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 145 (actual)

## Conditions studied

- Hypertension
- Dyslipidemias

## Interventions

- **DRUG:** HCP1701
- **DRUG:** Losartan
- **DRUG:** Amlodipine
- **DRUG:** Rosuvastatin and Ezetimibe

## Key facts

- **NCT ID:** NCT04074551
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-16
- **Primary completion:** 2020-03-17
- **Final completion:** 2020-03-17
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2020-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04074551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04074551, "A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04074551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*